OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Coleman on the Potential of Tisotumab Vedotin in Cervical Cancer

January 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential of tisotumab vedotin in cervical cancer.

Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML

January 19th 2021

Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

January 19th 2021

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Dr. Raghav on the Role of Molecular Profiling in Treatment Selection in mCRC

January 18th 2021

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer.

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

January 18th 2021

Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.

Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

January 18th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Dr. Cortes on the Future of Ponatinib in CML Treatment

January 18th 2021

Jorge E. Cortes, MD, discusses the future of ponatinib in the treatment of patients with chronic myeloid leukemia.

Dr. Stiles on Treatment Advances Made in Early-Stage Lung Cancer

January 18th 2021

Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.

Dr. Hong on the Potential Clinical Implications of the SURPASS Trial in Gastric/GEJ Cancer

January 18th 2021

David S. Hong, MD, discusses the potential clinical implications of the phase 1 SURPASS trial in gastric/gastroesophageal junction cancer.

Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management

January 18th 2021

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.

Dr. Harding on the Results of the SUMMIT Trial in HER2+ Biliary Tract Cancers

January 17th 2021

James J. Harding, MD, discusses the results of the ongoing, phase 2 SUMMIT basket trial in HER2-mutant advanced biliary tract cancers.

Dr. Zhu on the OS Results of the ClarIDHy Trial in IDH1+ Cholangiocarcinoma

January 17th 2021

Andrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.

Dr. Wainberg on the FIGHT Trial Results in FGFR2b+ Gastric/GEJ Cancer

January 16th 2021

Zev A. Wainberg, MD, of University of California, Los Angeles, discusses the results of the phase 2 FIGHT trial (NCT03343301) in FGFR2b-positive gastric/gastroesophageal junction (GEJ) cancer.

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

January 16th 2021

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Dr. Shitara on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer

January 15th 2021

Kohei Shitara, MD, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric/gastroesophageal junction cancer.

Dr. Fonseca Discusses Key Data in Multiple Myeloma

January 15th 2021

Rafael Fonseca, MD, discusses key data in multiple myeloma.

Dr. Kumar on Understanding the Safety Profiles of Combination Therapies in Multiple Myeloma

January 15th 2021

Shaji K. Kumar, MD, discusses the importance of understanding the safety profiles of combination therapies in multiple myeloma.

Dr. Ramalingam on the Potential of HER2 as a Driver Mutation in NSCLC

January 14th 2021

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Dr. Tolaney on the Need to Develop Additional Biomarkers in mTNBC

January 14th 2021

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Dr. Olin on the Rationale to Evaluate Menin Inhibitors in AML

January 14th 2021

Rebecca L. Olin, MD, MSCE, discusses the rationale to evaluate menin inhibitors in acute myeloid leukemia.